PHILADELPHIA, June 27, 2025 (GLOBE NEWSWIRE) --
MicroStrategy, Inc. (NASDAQ: MSTR):
If you are a current MicroStrategy, Inc. (NASDAQ: MSTR) shareholder who purchased MicroStrategy shares prior to April 30, 2024, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/microstrategy-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call us at 267-507-6085
Grabar Law Office is investigating claims on behalf of shareholders of MicroStrategy. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
WHY? As alleged in a recently filed securities fraud class action Complaint, MicroStrategy, Inc. (NASDAQ: MSTR), via certain of its officers, made materially false and misleading statements regarding Strategy’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the anticipated profitability of the Company’s bitcoin-focused investment strategy and treasury operations was overstated; (ii) the various risks associated with bitcoin’s volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
WHAT YOU CAN DO NOW: If you purchased MicroStrategy (NASDAQ: MSTR) shares prior to April 30, 2024 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/microstrategy-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #MicroStrategy $MSTR
Manhattan Associates, Inc. (NASDAQ: MANH):
Grabar Law Office is investigating whether certain officers and directors of Manhattan Associates, Inc. (NASDAQ: MANH) breached their fiduciary duties owed to the company.
If you have held Manhattan Associates, Inc. (NASDAQ: MANH) shares since prior to October 22, 2024, and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/manh-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085.
Why? A recently filed securities fraud class action complaint alleges that Manhattan Associates, Inc. (NASDAQ: MANH), through certain of its officers, provided investors with material information concerning Manhattan Associates’ expected revenue for the fiscal year 2025. These statements included, among other things, confidence in the Company’s ability to forecast guidance despite macroeconomic fluctuations, the growth potential of their professional services offerings, and the ability for their cloud revenue to drive revenue for its professional services.
The underlying complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Manhattan Associates’ forecasting ability for its professional services; notably, the Company was either not truly equipped to deliver “responsible targets” for growth or, otherwise, Manhattan Associates’ services were not equipped to achieve such targets. Finally, the Complaint alleges that such statements absent these material facts caused Plaintiff and other shareholders to purchase Manhattan Associates’ securities at artificially inflated prices.
What You Can Do Now: Current Manhattan Associates shareholders who have held Manhattan Associates shares since prior to October 22, 2024, are encourage to visit https://grabarlaw.com/the-latest/manh-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $MANH #ManhattanAssociates
Napco Security Technologies, Inc. (NASDAQ: NSSC) Shareholder Class Action Survives Motion to Dismiss:
If you are a Current Napco Security Technologies, Inc. (NASDAQ: NSSC) shareholder who has held Napco shares since prior to November 7, 2022, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Click here to join or learn more: https://grabarlaw.com/the-latest/Napco-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
Why? Key allegations in a recently filed securities fraud class action complaint against the company and certain of its officers have survived a motion to dismiss. That complaint alleges that Napco Security Technologies, Inc. (NASDAQ: NSSC), through certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that: (1) Napco failed to address any material weaknesses with internal controls regarding cost of goods sold ("COGS") and inventory; (2) Napco downplayed the severity of material weaknesses regarding their internal controls; (3) Napco’s unaudited financial statements from September 30, 2022 to the present included “certain errors” such as overstating inventory and understanding net COGS, resulting in overstated gross profit, operating income and net income for each period; (4) as a result, Napco would need to restate its previously filed unaudited financial statements for certain periods; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On April 11, 2025, the federal court determined that key allegations would survive Defendants’ motion to dismiss the complaint. In so holding, the court determined “Plaintiffs have adequately stated Exchange Act claims by pleading scienter [knowledge of wrongdoing] through defendants’ unusual stock sales and by plausibly alleging loss causation between the corrective announcement and stock price drop. Plaintiffs have also stated Securities Act claims against Napco and the underwriter defendants.” . . . “Taking the well-pleaded facts as true, there is no question that plaintiffs have adequately pled scienter. First, the stock sales were highly unusual in timing and amount. As to amount, the total proceeds of over $108 million from stock sales by the officer defendants weigh in favor of a motive. . . . And the officer defendants sold hefty percentages of their holdings – 48.5% for Soloway and 45.5% for Buchel.”
What To Do Now: If you have held Napco shares since before November 7, 2022 and would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/Napco-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $NSSC #NAPCO
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
If you have held Treace Medical Concepts (NASDAQ: TMCI) shares continuously since prior to May 8, 2023, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/treace-shareholder-investigation/, or contact Joshua H. Grabar at jgrabar@grabarlaw.com or call 267-507-6085 to learn more.
Why? A recently filed securities class action complaint alleges that, Treace Medical Concepts, Inc. (NASDAQ: TMCI), via certain of its officers, made materially false and/or misleading statements and failed to disclose adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical’s revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What You Can Do Now: Current Treace shareholders who have held Treace shares since prior to May 8, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/treace-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085. #Treace $TMCI
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
